Bristol Myers Q1 Profit Beats Estimates on Eliquis, Cancer Drug Sales
Bristol Myers Squibb reported first-quarter adjusted earnings of $1.00 per share, exceeding analyst expectations of $0.95. The beat was driven by better-than-expected growth of blood thinner Eliquis and newer cancer medicines, sending shares up 4%.
Key Numbers
Bristol Myers Squibb (BMY) reported first-quarter adjusted earnings of $1.00 per share, beating Wall Street estimates of $0.95. The strong performance was fueled by better-than-expected sales of blood thinner Eliquis and newer cancer drugs, sending shares up 4% in premarket trading.
Key Financial Results
| Metric | Q1 2026 | vs. Estimates |
|---|---|---|
| Adjusted EPS | $1.00 | Beat ($0.95 est.) |
| Revenue | Not disclosed | - |
| Net Income | Not disclosed | - |
Highlights from the Release
The company attributed the strong quarter to:
- Eliquis: The blood thinner, co-marketed with Pfizer (PFE), posted better-than-expected growth.
- Newer cancer drugs: Sales exceeded expectations, boosting overall revenue.
Guidance
Bristol Myers did not provide specific guidance for the next quarter or fiscal 2026 in this release.
Impact on Stock
Shares rose 4% in premarket trading following the announcement, reflecting investor optimism over the earnings beat.
What This Means for Investors
The earnings beat underscores the strength of Bristol Myers' product portfolio, with continued growth from Eliquis despite looming patent expirations and success from newer oncology drugs. However, investors should monitor patent developments and competitive dynamics.
Frequently Asked Questions
Found this useful? Share it